Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -75.13% is 21% below its 5-year average of -61.98%, around the middle of its 5-year range (-212.91%–37.21%).
30.82% below its 12-month average of -57.43%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -13.99%.
RETURN ON ASSETS (ROA)
-75.13%
RETURN ON ASSETS (ROA) AVG TTM
-57.43%
RETURN ON ASSETS (ROA) AVG 3Y
-49.05%
RETURN ON ASSETS (ROA) AVG 5Y
-61.98%
RETURN ON ASSETS (ROA) AVG 10Y
-70.09%
RETURN ON ASSETS (ROA) AVG 15Y
-55.94%
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-30.82%
CURRENT VS 3Y AVG
-53.17%
CURRENT VS 5Y AVG
-21.21%
CURRENT VS 10Y AVG
-7.18%
CURRENT VS 15Y AVG
-34.31%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-133.03%
vs the sector median at left
Silo Pharma, Inc.
Market Cap
$1.64M
Return on Assets (ROA)
-75.13%
TTM Avg
-57.43%
3Y Avg
-49.05%
5Y Avg
-61.98%
Market Cap
$1.52M
Return on Assets (ROA)
-148.13%
TTM Avg
-399.46%
3Y Avg
-266.31%
5Y Avg
-266.31%
Market Cap
$1.49M
Return on Assets (ROA)
-36.88%
TTM Avg
-64.67%
3Y Avg
-76.84%
5Y Avg
-289.12%
Market Cap
$1.47M
Return on Assets (ROA)
-23.39%
TTM Avg
-29.27%
3Y Avg
-34.02%
5Y Avg
-43.63%
Market Cap
$1.81M
Return on Assets (ROA)
-264.51%
TTM Avg
-155.32%
3Y Avg
-198.50%
5Y Avg
-155.28%
Market Cap
$1.46M
Return on Assets (ROA)
-111.51%
TTM Avg
-71.56%
3Y Avg
-64.13%
5Y Avg
-49.86%
Market Cap
$1.83M
Return on Assets (ROA)
-4123.80%
TTM Avg
-624.65%
3Y Avg
-938.33%
5Y Avg
-768.81%
Market Cap
$1.84M
Return on Assets (ROA)
-101.83%
TTM Avg
-124.53%
3Y Avg
-109.00%
5Y Avg
-89.33%
Market Cap
$1.84M
Return on Assets (ROA)
-137.72%
TTM Avg
-127.80%
3Y Avg
-167.94%
5Y Avg
-149.58%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Silo Pharma, Inc. (SILO) | $1.64M | -75.13% | -57.43% | -49.05% | -61.98% |
| Lakewood-Amedex Biotherapeutics, Inc. (LABT)vs › | $1.52M | -148.13% | -399.46% | -266.31% | -266.31% |
| PMGC Holdings Inc. (ELAB)vs › | $1.49M | -36.88% | -64.67% | -76.84% | -289.12% |
| NEXGEL, Inc. (NXGL)vs › | $1.47M | -23.39% | -29.27% | -34.02% | -43.63% |
| Alaunos Therapeutics, Inc. (TCRT)vs › | $1.81M | -264.51% | -155.32% | -198.50% | -155.28% |
| Curis, Inc. (CRIS)vs › | $1.46M | -111.51% | -71.56% | -64.13% | -49.86% |
| Profusa, Inc. Common Stock (PFSA)vs › | $1.83M | -4123.80% | -624.65% | -938.33% | -768.81% |
| Beyond Air, Inc. (XAIR)vs › | $1.84M | -101.83% | -124.53% | -109.00% | -89.33% |
| Tenon Medical, Inc. (TNON)vs › | $1.84M | -137.72% | -127.80% | -167.94% | -149.58% |
| INVO Fertility, Inc. (IVF)vs › | $1.42M | -20.46% | -67.47% | -117.99% | -101.96% |
ROA
-75.1%
ROE
-91.5%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -55.59% |
| 2024-12-31 | -59.27% |
| 2023-12-31 | -47.77% |
| 2022-12-31 | -33.57% |
| 2021-12-31 | 37.21% |
| 2020-12-31 | -212.91% |
| 2019-12-31 | -205.18% |
| 2018-12-31 | -113.33% |
| 2017-12-31 | 21.72% |
| 2016-12-31 | -85.64% |
| 2015-12-31 | -16.71% |
| 2014-12-31 | -13.59% |
| 2013-12-31 | 1.49% |
| 2012-12-31 | -14138.35% |
| 2011-12-31 | -2842.64% |
| 2010-12-31 | 0.00% |
